DOCSLIB.ORG

Research Frontiers in Fertility Regulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

July 1980, Volume 1, Number 1 Northwestern University 1040 Passavant Pavilion 303 East Superior Street Chicago, Illinois 60611 Editor: Gerald I. Zatuchni, M.D., M.Sc. Managing Editor: Kelley Osb--n This publication is supported by AID/DSPE-C-0035 RESEARCH FRONTIERS IN FERTILITY REGULATION review of past and current This report is the premiere issue of a series designed to present a comprehensive regulat'on and contraceptive develop­ research information and experience on selected major topics in fertility with the best possible summary ment. The aim of the series is to provide the scientific and technical community six times annually. As new of the state of the art with regard to each topic. The reports will appear approximately updated and rei-sued. developments occur in this rapidly changing field, the reports will be appropriately without charge by specific request to Additional copies of this publication and future issues may be obtained PARFR at the indicated address. LONGACTING STEROIDAL CONTRAEPTIVE . r Lee R. Bek, Ph.D. Donald R. Cowar, Ph.D. "ValeieZ. PS Asocae rfesor. Associate Diedor .ewh~mVr Obs Depatmen ofObstrcs Appflsd Sence Research Depa ivieWtof nufhem Ruwarh -It and Gorym"oo Universiyof Alabma Birmingham, Alabama UniversitfAlabarm BRalvignhamn *~zam of minimal intervention and The need for effective, safe, and easy-to-use contracep- The therapeutic concept through the programmed deliv­ tives has not diminished with the advent of the pill and how it can be achieved is illustrated in Figure 1. the intrauterine device (IUD). On the contrary, concern ery of steroidal contraceptives levels of a hypothetical regarding the safety of conventional contraceptives con- The curves compare blood conventional or improved dellv­ tinues to stimulate new research. One approach to the steroid following either delivery isby the oral improvement of the effectiveness, safety, and acceptabil- ery. In this example, conventional is achieved by the use of ity of steroidal contraceptives is to develop long-acting route, and improved delivery which provides programmed preparations and methods of delivery which provide an injectable formulation of the drug necessary for con­ medication. This rationale is based on the release. The blood level programmed by a narrow zone. Values in knowledge that side effects of steroid hormones are traception is represented dose constitute over­ dose-dependent. Accordingly, the degree of risk changes excess of the optimal therapeutic potential for dose-dependent in proportion to the dose. The preferred dose isone that medication with a greater values below the effective range evokes contraception with minimal risk. side effects, whereas Z OVERDOSE WITH cnF RISK OF SIDE W EFFECTS L- THE RANGE I - --- -­-­ OF MINIMAL - .INTERVENTION ~RISK UNDERDOSEOF WITH REGNANCY 1It ORAL PATTERN Figure 1. Blood levels of ahypotheti­ 8 ORLED PREGNANCY cal steroid following either oral ad­ or programmed deliv­ 1 2 3 4 5 6 7 8 9 10 11 12 ministration TIME ery. F A. Long-Acting Contraceptives E Figure 2. Long-acting steroidal contraceptive systems under current development. A. Injectable depot formulations. B. Non-biodegradable subdermal Implants, capsules, and rods. C. Medicated intrauterine devices. D. Medicated intravaginal devices. E. Medicated intracervical devices. F. Biodegradable systems. D C can result in contraceptive failure. Minimal intervention (C,D,E); and biodegradable systems that release fertility control occurs when the steroid is maintained steroids by diffusion and/or erosion of a biodegradable within the therapeutically effective dose range. Oral ad- polymer (F). ministration results in immediate high blood levels that decrease with time, and repetitive doses must be given Two different approaches have been used in the attempt at frequent intervals to keep the blood levels within the to achieve minimal intervention fertility control, the systems engineering effective zone. This results in blood steroid fluctuations, pharmacologic approach, and the represented by the pe;'ks of which exceed what is necessary for con- approach. The pharmacologic approach, compounds hav­ traception. injectable steroids, involves the use of ing iatrinsic chemical properties which provide slow re­ The injectable controlled-release system meters the iease. These include solubility of the drug in the body steroid into the blood at a controlled rate designed to fluid at the injection site, affinity for receptors in the maintain the blood level in the desired range, thereby body fluid and tissues, and rate of metabolism and achieving minimal intervention fertility control. Control- excretion from the body. The systems engineering ap­ led release allows for reduction in the total amount of pro.ch utilizes inert drug carriers to control the rate of steroid administered over a prolonged period of time, drug release. Although the degree of cor, rol may vary and reduces the chance of human error by eliminating from one carrier to the next, the systems approach can the need for repetitive self-administration, be distinguished from the plharmacologic approach on The methods which have been employed to achieve neitherthe basisa bodyof a norcontrolled-release a drug component. mechanism which is using steroidal hor­ minimal intervention fertility control mones are illustrated in Figure 2. These include: steroi- Long-acting steroidal contraceptive systems can be dal preparations selected for slow release and injectabil- further classified as those designed for systemic or local ity (A); subdermal implants in the form of Silastic cap- delivery. The implant and injectable systems, as well as sules and rods containing progestogens which diffuse medicated intravaginal devices, are designed for sys­ slowly from the implant (B); medicated devices which temic delivery; whereas medicated intrauterine and in­ release steroids locally in the uterus, vagina, and cervix tracervical devices are intended for local delivery. The 2 rationale for local delivery is to reduce the steroid load A comparison of 6- and 3-month treatment regimens, the target organ. ,,sing 300 and 150 mg MPA respectively, revealed 40% even further by direct delivery to drug-related dropouts in the 6-month group, compared tou oly 25% in th group 4) a ( 1 The effort to develop new long-acting steroidal formula- tonly 6- ind 3-month r oup interal ( 111) tions and improved delivery systems for existing com- compared 6- and 3-month treatment intervals (450 and pounds represents a goal-oriented task which includes and found a greater preg­ both applied and basic research of a diverse nature. The 150 mg MPA respectively) vs. purposebpurped of thisthscommicaiearh and communication isoto reviewreiewe the atestateTf of 0.1069)nancy rate during with 220,530 the longer-acting woman months system of use.(0.4943 steroidal contraceptive the art relating to long-acting systems, with emphasis on systems that have the poten- The major side effect of MPA is irregular bleeding. tial to provide minimal intervention fertility control. Bleeding often increases at first, but decreases with repeated injections, leading to amenorrhea. in one study, 35% of 272 women became amenorrheic during Injectable Depot Formulations therapy (79), and another study reports a 50% incidence of amenorrhea after 3 years of continuous therapy The first contraceptive steroids were syn- (103). Side effects other than bleeding irregularities thetic progestogens which had to be adminis- which have been reported include decreases in libido, tered at frequent intervals because they had short weight changes, edema, and headaches (29). biologic half-lives. The synthesis and screening of new compounds led to the discovery of structures having Blood levels following injection of 150 mg of MPA longer durations of action which made administration by reached a mean value of 3.57 ng/ml by one week injection an attractive alternative to oral contraception, post-treatment and declined to 0.6 ng/ml by 12 weeks levels in the 10 to 25 ng/ml range at 5-20 Two progestogens, mcdroxyprogesterone acetate (MPA) (72). Blood decreased to 5 to 10 ng/ml by 30 and norethindrone enanthate (NET-EN) emerged from days post-treatment followed by a more gradual decline this early work as promising injectable formulations. days post-treatment, 260 (72, 73). The minimum blood level of Upjohn Pharmaceuticals developed MPA under the through day to inhibit ovulation is 0.5-1 ng/ml. trade name Depo-Provera, and Schering AG developed MPA necessary NET-EN under the trade name Noristat. Other proges- Delay in return to fertility may be a side effect of MPA togens which have been administered by injection in- treatment. Conception or return to normal menses oc­ clude hydroxyprogesterone caproate (Delalutin, curred following discontinuation of treatment (250 mg Squibb), dihydroxyprogesterone acetophenide (Dela- MPA every 3 months) within four to seven months in droxate, Squibb), levonorgestrel undecylate (Schering 183 women following 38,599 months of use (78). In AG), and levonorgestrel nonanoate (Schering AG). another study, 50% of the women desiring pregnancy months post-treatment (79). Medroxyprogesterone acetate (MPA) was first used for conceived at 7 to 12 an 80% pregnancy rate within treatment of habitual abortion and endometriosis. A McDaniel (88) reported Pardthaisong (89) claim that single dose (Ig to 4 g) of MPA for the treatment of 12 months. McDaniel and MPA contraception is no premature labor was found to protect against pregnancy return to fertility
Recommended publications
  • Sterilization and Abortion Policy Billing Instructions

    Sterilization and Abortion Policy Billing Instructions

    Sterilization and Abortion Policy Billing Instructions Table of contents Table of contents ...................................................................................................................................... 1 Hysterectomy ............................................................................................................................................ 2 Acknowledgement forms ..................................................................................................................... 2 Prior authorization requirements ......................................................................................................... 2 Covered services ................................................................................................................................... 2 Intrauterine Devices and Subdermal Implants ......................................................................................... 4 Family planning: sterilization .................................................................................................................... 4 Prior authorization requirements ......................................................................................................... 5 Covered services ................................................................................................................................... 5 Abortion .................................................................................................................................................... 6 Claim
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 65 / No. 3 July 29, 2016 U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................2 How to Use This Document ...............................................................................3 Keeping Guidance Up to Date ..........................................................................5 References ................................................................................................................8 Abbreviations and Acronyms ............................................................................9 Appendix A: Summary of Changes from U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 ...........................................................................10 Appendix B: Classifications for Intrauterine Devices ............................. 18 Appendix C: Classifications for Progestin-Only Contraceptives ........ 35 Appendix D: Classifications for Combined Hormonal Contraceptives .... 55 Appendix E: Classifications for Barrier Methods ..................................... 81 Appendix F: Classifications for Fertility Awareness–Based Methods ..... 88 Appendix G: Lactational
  • Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection

    Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection

    Patient Instructions for Post-Vasectomy Fertility Test: Semen Specimen Collection Semen specimen 12 weeks after your vasectomy: Twelve weeks (3 months) after your vasectomy, you should collect a semen specimen in the container provided to you by the Urology Department. It is recommended that you have at least 20 ejaculations within the 12-week period after your vasectomy. Depending on the results of your initial sample, you may be asked by your physician to provide another sample. You must utilize an alternate method of contraception until cleared by your physician. You are considered fertile following vasectomy until, as per the American Urological Assn. recommendations, at least one semen analysis shows no fertile sperm. On rare occasions, the vasectomy can fail and the vas deferens tubes can rejoin. Your semen specimen can be brought by yourself to the Urology Clinic only if: It can be in the laboratory within one hour of collection, and It is kept at room temperature during that time. It is suggested, however, that you create your semen specimen while you are at the Urology Clinic. Your semen specimen deposit should be scheduled in advance by Kathy Stevens: call 434-924-9548 or 434- 924-9560. Please note the following important instructions and guidelines for semen collection: The sample should be collected after a minimum of 2 days, and a maximum of 7 days, of sexual abstinence. If you choose to collect the specimen at home, it must be collected in a clean specimen container with a secure lid, such as one with a screw-on cap.
  • Opinion Study on Vasectomy, Sterilized Version of Male Keywords: Vasectomy; Contraception; Sperm; Gonads Contraception

    Opinion Study on Vasectomy, Sterilized Version of Male Keywords: Vasectomy; Contraception; Sperm; Gonads Contraception

    Opinion iMedPub Journals Journal of Contraceptive Studies 2017 http://www.imedpub.com ISSN 2471- 9749 Vol. 2 No. 1:5 DOI: 10.21767/2471-9749.100028 Opinion study on Vasectomy, Sterilized Audrey Kanes Version of Male Contraception Department of Endocrinology, Universidad de São Paulo, Brazil Abstract Corresponding author: Audrey Kanes Vasectomy, it is well known heard around the world as the extreme perfect [email protected] sterilized process of contraception which is known to be synonym of contraception for males, male animals too. Amid vasectomy, a medicinal services supplier closes Professor, Department of Endocrinology, or obstructs the tubes that convey sperm. At the point when the tubes are shut, Universidad de São Paulo, Brazil. sperm can't leave a man's body and cause pregnancy. Sperms are made in the Gonads will go through two tubes called the vasa differentia to different organs Tel: +55 19 3521-7000 and blend with original liquids to frame semen. Vasectomy obstructs every vas deferens and keeps sperm out of the original liquid. Sperms are consumed by the body as opposed to being discharged. Without your thickened sperm (discharge) can't bring the suspect chance on pregnancy. Citation: Kanes A. Opinion study on Vasectomy, Sterilized Version of Male Keywords: Vasectomy; Contraception; Sperm; Gonads Contraception. J Contracept Stud. 2017, 2:1 Received: March 02, 2017, Accepted: March 09, 2017 Published: March 16, 2017 Sterilized Procedure There are diverse routes for men to be cleaned. One write does not require an entry point - a cut. Alternate sorts of vasectomy require an entry point. Cut strategies take around 20 min [1-3].
  • Sterilization As a Family Planning Method

    Sterilization As a Family Planning Method

    December 2018 | Fact Sheet Sterilization as a Family Planning Method Sterilization is a permanent method of contraception, and is the most commonly used form of family planning among couples both in the United States and worldwide. For men and women who no longer want to have children, sterilization offers a permanent, safe, cost-effective and efficacious way to prevent unintended pregnancy. Male sterilization is less common than female sterilization, but both are nearly 100% effective at preventing pregnancy. The Affordable Care Act’s no-cost coverage of sterilization has increased the affordability of the procedure for women, but it is still unclear the overall effect this will have on future utilization rates. Recent changes to insurance coverage policy, broader availability of long- acting contraceptives, as well as changes in the health care delivery system may reshape the choices that men and women make regarding the use of sterilization as a contraceptive method. This fact sheet explains the types of sterilization procedures available to women and men, reviews private insurance and Medicaid coverage policy, and discusses issues that affect availability in the U.S. Female Sterilization Female sterilization is an Figure 1 outpatient surgical Prevalence of Sterilization Among Women 15 to 44 Who procedure. The procedure Report Using a Reversible or Permanent Contraceptive blocks the fallopian tubes, Method, 2013-2015, by Selected Characteristics preventing eggs from All women, ages 15-44 22% travelling down the tubes to the uterus and blocking Ages 25-34 19% sperm from fertilizing the Ages 35-44 39% egg. Data from the Centers for Disease Control and Black 26% Hispanic 25% Prevention (CDC) show that White 21% among women ages 15 to 44 who use a contraceptive ≥ 200% FPL 16% method, one in five used ≤ 200% FPL 29% tubal ligation as their method 1 of contraception.
  • Anordrin Eliminates Tamoxifen Side Effects Without Changing Its

    Anordrin Eliminates Tamoxifen Side Effects Without Changing Its

    www.nature.com/scientificreports OPEN Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity Received: 26 August 2016 Wenwen Gu1,*, Wenping Xu2,*, Xiaoxi Sun3, Bubing Zeng2, Shuangjie Wang1, Nian Dong4, Accepted: 31 January 2017 Xu Zhang1, Chengshui Chen4, Long Yang5, Guowu Chen3, Aijie Xin3, Zhong Ni6, Jian Wang1 & Published: 07 March 2017 Jun Yang1 Tamoxifen is administered for estrogen receptor positive (ER+) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER+ breast cancer than five years of such treatment. Tamoxifen was also approved by the FDA as a chemopreventive agent for those deemed at high risk for the development of breast cancer. The side effects are of substantial concern because of these extended methods of tamoxifen administration. In this study, we found that anordrin, marketed as an antifertility medicine in China, inhibited tamoxifen-induced endometrial epithelial cell mitosis and NAFLD in mouse uterus and liver as an anti-estrogenic and estrogenic agent, respectively. Additionally, compared with tamoxifen, anordiol, the active metabolite of anordrin, weakly bound to the ligand binding domain of ER-α. Anordrin did not regulate the classic estrogen nuclear pathway; thus, it did not affect the anti- tumor activity of tamoxifen in nude mice. Taken together, these data suggested that anordrin could eliminate the side effects of tamoxifen without affecting its anti-tumor activity. Tamoxifen was the first FDA-approved drug for breast cancer patients with positively expressed estrogen recep- tors (ER)1. However, tamoxifen also induces side effects, such as uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD).
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al

    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
  • Threat to the PHLS

    Threat to the PHLS

    Br Med J (Clin Res Ed): first published as 10.1136/bmj.290.6468.579 on 23 February 1985. Downloaded from LONDON, SATURDAY 23 FEBRUARY 1985 MEDICAL JOURNAL Threat to the PHLS In its drive for economy the government has included among Furthermore, the creation of the Communicable Disease its targets the Public Health Laboratory Service of England Surveillance Centre by the PHLS on behalfofthe DHSS and and Wales. The proposal under consideration is the transfer the Welsh Office has required additional epidemiological of some (or possibly all) the Service's 52 regional and area resources for the national surveillance and control of laboratories to the control of health authorities. The argu- communicable disease, functions previously performed by ment seems to be that in the existing joint PHLS-hospital the departments. The laboratory reporting system has been laboratories most of the specimens examined are for the expanded with contributions from hospital laboratories, diagnosis of infection in individual patients, so that it would individual consultants, and the Royal College of General be logical to transfer these laboratories to the control of the Practitioners helping to provide a fuller epidemiological National Health Service. picture. Many more field investigations of outbreaks have The joint PHLS-hospital laboratories became the pattern been undertaken, as publications in the BMJ have shown. in the 1960s by agreement between the PHLS and the The result has been an unfortunate decline in the multicentre Department ofHealth and Social Security. The reasons were studies and epidemiological research for which the PHLS partly economic but mainly because joint laboratories alone structure is particularly suited.
  • Improving the Safety and Effectiveness of Contraception in China: a Case-Study in Promotion and Improvement of Family Planning

    Improving the Safety and Effectiveness of Contraception in China: a Case-Study in Promotion and Improvement of Family Planning

    WHO/RHR/HRP/08.07 UNDP/UNFPA/WHO/WORLD BANK Special Programme of Research, Development and Research Training in Human Reproduction (HRP) Improving the safety and effectiveness of contraception in China: a case-study in promotion and improvement of family planning Reviewer Barbara L.K. Pillsbury International Health & Development Associates, Washington, DC, USA With assistance from William Winfrey Futures Institute, Glastonbury, CT, USA for the economic analysis UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP). External evaluation 2003–2007; Improving the safety and effectiveness of contraception in China: a case-study in promotion and improvement of family planning. © World Health Organization 2008 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
  • Reproductive Health Guideline Appendix 3 – Search Strategies

    Reproductive Health Guideline Appendix 3 – Search Strategies

    SUPPLEMENTARY APPENDIX 3: Search Strategies 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases All searches initially run on 11/8/2017 and updated on 5/8/2018. Searches run from database inception to 5/8/2018. PUBMED Syntax Guide for PubMed [MeSH] = Medical Subject Heading [Text Word] = Includes all words and numbers in the title, abstract, other abstract, MeSH terms, MeSH Subheadings, Publication Types, Substance Names, Personal Name as Subject, Corporate Author, Secondary Source, Comment/Correction Notes, and Other Terms - typically non-MeSH subject terms (keywords)…assigned by an organization other than NLM [MeSH subheading] = a Medical Subject [Title/Abstract] = Includes words in the title Heading subheading, e.g.
  • Effect of A-Nor Steroids and Oestradiol on Progesterone Production By

    Effect of A-Nor Steroids and Oestradiol on Progesterone Production By

    Effect of A-nor steroids and oestradiol on progesterone production by human luteal cells Wang Han-zheng, Lu Shu-hua, Shen Wei-xiong, Sun Zhi-da, Zhou Wei, Wu Yu-fen and Zhou Mei-rong Shanghai Institute of Planned Parenthood Research, *Shanghai Lu-wan District Maternity and Child Health Hospital and fRen-jin Hospital, Shanghai No. 2 Medical University, Shanghai, China Summary. Cell suspensions were prepared from human corpora lutea obtained during the mid-luteal phase. Progesterone production was assessed after short-term incubation of luteal cell suspensions. Luteal cells were very sensitive to hCG, the concentration required for 50% maximum response being 0\m=.\01i.u./ml, and the response was 5 times higher than the basal production. Oestradiol (1\p=n-\100\g=m\m)induced a significant dose-related decrease in both basal and hCG-stimulated progesterone production. The A-nor steroidal compounds anordrin and AF-45 reduced hCG-stimulated progesterone production only at the high concen- tration of 100 \g=m\m.The ED50 values were approximately 3 \g=m\m,75 \g=m\mand 100 \g=m\mfor oestradiol, AF-45 and anordrin respectively. Anordrin showed no significant effects on basal progesterone production. In addition, oestradiol markedly inhibited the activity of 3\g=b\-hydroxysteroiddehydrogenase in luteal cells, expressed by the conversion of pregnenolone to progesterone, but the inhibitory effects of anordrin and AF-45 were negligible or relatively low. The effects of anordrin and AF-45 were different from those of oestradiol on pro- gesterone production by human luteal cells in vitro, indicating that neither substance is likely to be a useful luteolytic agent in women.